

Venue of the Congress

Hotel Mediterraneo

Via Ponte di Tappia 25 - 80133 Napoli - Tel. +39 081 7970001
e-mail: info@mediterraneanapoli.com - www.mediterraneanapoli.com



Thanks for the support to



8TH MEETING ON EXTERNAL QUALITY ASSESSMENT IN MOLECULAR PATHOLOGY

OFFICIAL ANNUAL MEETING OF IQNPATH

Hotel Mediterraneo • Naples, 24-25 May, 2019

Segreteria AIOM



Via Enrico Nöe, 23 - 20133 Milano
tel. 02 70630279 - fax 02 2360018
aiom.segretario@aiom.it - www.aiom.it

Segreteria Organizzativa



Sede di Milano
Via Enrico Nöe, 23
20133 Milano
tel. 02 26683129
fax 02 59610555
info@aiomservizi.it

Sede di Roma
Via D. Cimarosa, 18
00198 Roma
tel. 06 8553259
fax 06 8553221
info@aiomservizi.it

PROGRAM

FRIDAY, MAY 24



Chair: N. Normanno

09.00	Welcome and Opening <i>A. Bianchi, G. Botti</i>
09.30 - 11.00	Joint ESMO-AIOM-IQN Path session The current status of biomarker testing in Europe <i>The aim of this session is to discuss with the different stakeholders (patients, medical oncologists, regulatory agencies, pharmas) the current status of access to and quality of biomarker testing in Europe.</i> Chairs: N. Normanno, A. Ryska, E. Torlakovic
09.30 - 09.45	The relevance of biomarkers in precision oncology (ESMO) (<i>E. Martinelli</i>)
09.45 - 10.05	The access to biomarkers in Europe: the patients' perspective (ECPC) (<i>F. de Lorenzo</i>)
10.05 - 10.20	The quality of biomarker testing in Europe (ESP) (<i>A. Ryska</i>)
10.20 - 10.35	The pharmas' view on biomarkers access and quality (EFPIA) (<i>C. Dollins</i>)
10.35 - 10.50	The IARC collaboration for cancer classification and Research (IC3R) (<i>I. Cree</i>)
10.50 - 11.10	Discussion on an IQN Path proposal
11.10 - 11.40	Coffee break
11.40 - 13.30	Biomarkers for immunotherapy <i>In this session, the current status of biomarkers for immunotherapy will be discussed. An update of the current projects on PD-L1 and TMB testing form IQN Path and associated EQAs will be also presented.</i> Chairs: M. Dietel, J. Qiu, E. Torlakovic
11.40 - 11.55	The evolving landscape of biomarkers for immune checkpoint inhibitors (<i>P. Hofman</i>)
11.55 - 12.10	IQNPath PD-L1 Digital slide initiative (<i>J. Qiu, E. Torlakovic</i>)
12.10 - 12.20	The DGP-QUIP PD-LI and TMB EQA program (<i>M. Dietel</i>)
12.20 - 12.30	The TMB IQNPath Project (<i>F. Fenizia</i>)
12.30 - 13.00	Discussion focused on the harmonization of EQA initiatives
13.00 - 14.00	Lunch

14.00 - 15.30	The evolution of liquid biopsy in the management of cancer patients Chairs: S. Deans, E. Dequeker, E. Rouleau <i>In this session, the current status of the clinical implementation of liquid biopsies in clinical practice will be discussed.</i>
14.00 - 14.20	Tumor heterogeneity and liquid biopsy (<i>N. Valeri</i>)
14.20 - 14.40	The results of the IQNPATH EQA on liquid biopsy testing (<i>S. Deans</i>)
14.40 - 15.10	Discussion: focus on EQA issues
15.10 - 16.40	Technology improvements Chairs: N. Normanno, C. Pinto, E. Torlakovic
16.40 - 17.00	Tea break
17.00 - 18.00	General Meeting IQN Path (<i>open to all IQN Path members</i>)

SATURDAY, MAY 25

09.00 - 10.30	The relevance of fusion genes in cancer treatment and the challenge for testing <i>This session will address the new treatment options for patients carrying fusion genes and highlight the challenges for testing fusions in cancer.</i> Chairs: J. Qiu, D. Tiniakos, E. Torlakovic
09.00 - 09.20	Fusion genes as targets for therapeutic intervention in cancer (<i>M. Milella</i>)
09.20 - 09.40	Assessment of fusion genes: pros and cons of the different testing strategies (<i>F. Penault-Llorca</i>)
09.40 - 10.00	The IQN Path proposal for a pilot EQA scheme for fusion genes testing (<i>N. Wolstenholme</i>)
10.00 - 10.30	Discussion: focus based on EQA for fusion genes testing
10.30 - 10.45	Coffee break
10.45 - 12.00	BRCA and HRD testing in cancer Chairs: S. Deans, E. Rouleau, N. Wolstenholme
10.45 - 11.05	BRCA and HRD targeting drugs in clinical development (<i>D. Lorusso</i>)
11.05 - 11.25	Implications of BRCA testing in cancer (<i>E. Rouleau</i>)
11.25 - 11.40	Results of the BRCA variant classification EQA (<i>S. Deans</i>)
11.40 - 12.00	Discussion on an IQN Path proposal
12.00 - 13.30	Restricted session of IQN Path academic members on future projects (<i>N. Normanno, E. Torlakovic</i>)
13.30 - 14.30	Lunch